Improvement of Obesity and Type 2 Diabetes (T2D) by Oral Semaglutide (Rybelsus) and Super-Low Carbohydrate Diet (LCD)

For novel oral hypoglycemic agent (OHA), semaglutide (Rybelsus) has been attracted attention. Patient is 41-year-old hospital staff with obesity, who was pointed out 7.7% of HbA1c with weight 101kg in June 2020. He continued petite-low carbohydrate diet (LCD) for 8 months with weight reduction 3kg. Successively, he applied super-LCD for 7-months and showed 7kg reduction and HbA1c 5.6% in Sept 2021. He took Rybelsus 3mg per os from Mar 2022 and showed 88kg and 5.5% in Nov 2022. LCD brought improvement of ALT from 97 to 27 U/L for 30 months. Thus, LCD and Rybelsus showed satisfactory clinical effect.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.